FindTrial
Sign In

Expression of Enhancer of Zeste Homologue 2 (EZH2) and CD49f in breast cancer

Expression of Enhancer of Zeste Homologue 2 (EZH2) and CD49f in breast cancer and its association with clinicopathological features - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/069977
Enrollment
40
Registered
2024-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: NIL: NIL

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed female patients of breast carcinoma whose biopsy specimens are received in Department of Pathology, MAMC

Exclusion criteria

Exclusion criteria: Patients with prior neoadjuvant chemotherapy and/or radiation therapy

Design outcomes

Primary

MeasureTime frame
The prevalence of EZH2 and CD49f in breast carcinomaTimepoint: Baseline—

Secondary

MeasureTime frame
1) The association of EZH2 and CD49f with clinicopathological features of breast carcinoma like clinical stage, histological grade, tumor size and Tumor Infiltrating Lymphocytes(TILs) 2) The association of EZH2 and CD49f with percentage of Estrogen receptor, Progesterone receptor, Her2neu, Ki67 statusTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Reena Tomar

Maulana Azad Medical College

drreenat@yahoo.com9711972630

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026